AFMD - Affimed jumped 10% after Q3 beat robust growth in top-line of 402%

Affimed ([[AFMD]] +10.3%) Q3 results:Revenue of €10.6M (+402.4% Y/Y).Operating Loss: (€2.9M) (+76.6%); Net Loss: (€6.0M) (+44.9%); Loss Per Share: (€0.07) (+58.8%).Quick Assets: €97.3M, with anticipated cash runway into 1H of 2023.Upcoming milestones: AFM13 pTCL REDIRECT monotherapy study's interim analysis expected during 1H of 2021.The initiation of the Phase 1 study of drug  RO7297089 in patients with relapsed or refractory multiple Myeloma with Genentech triggered a milestone payment recognized in the 3Q.Previously: Affimed EPS beats by €0.01, beats on revenue (Nov.10).

For further details see:

Affimed jumped 10% after Q3 beat, robust growth in top-line of 402%